MedifocusHealth

Pemetrexed (Alimta), a new antifolate chemotherapeutic agent, has been shown to be an effective treatment option for patients with advanced NSCLC.

Vinorelbine (Navelbine), a semisynthetic vinca alkaloid drug, has been shown to be an effective and well-tolerated palliative treatment option for elderly patients with NSCLC.

Irinotecan (CPT-II; Camptosar) has demonstrated efficacy for the treatment of small cell lung cancer and also appears to be promising for the treatment of non-small cell lung cancer.

Researchers are evaluating the efficacy of tirapazamine, a prototype drug for a novel class of therapeutic agents called "hypoxic cytotoxins" that are designed to target tumor hypoxia, for the treatment of non-small cell lung cancer.

Researchers from Italy, recently reported that a surgical technique called sleeve lobectomy might be an alternative to pneumonectomy in some patients with non-small cell lung cancer.

Researchers are evaluating the efficacy of combination therapy with exisulind and docetaxel in patients with advanced NSCLC. Exisulind is an oral anticancer agent that was originally developed for the chemoprevention of colorectal cancer and is now being investigated for the treatment of non-small cell lung cancer.

Clinical trials are ongoing to evaluate the efficacy of trastuzumab (Herceptin), a humanized monoclonal antibody that has been approved for the treatment of advanced breast cancer, for the treatment of non-small cell lung cancer.

Researchers are evaluating a platinum-free combination of gemcitabine, ifosfamide, and Navelbine (GIN) for the treatment of advanced non-small cell lung cancer.

Information regarding ongoing clinical studies in your area can be obtained at the Clinical Trials Listing Service at http://www.centerwatch.com